Withdrawal of Inhaled Corticosteroids in Patients with COPD – A Prospective Observational Study

References

• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2020. Available from: www.goldcopd.org. Accessed April 28, 2020.
   Google Scholar
• Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35(1):71–86. doi:10.1016/j.ccm.2013.10.004
   PubMed Web of Science ®Google Scholar
• Vestbo J. COPD: definition and phenotypes. Clin Chest Med. 2014;35(1):1–6. doi:10.1016/j.ccm.2013.10.010
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Calle M, Soler-Cataluña JJ. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch Bronconeumol. 2012;48(3):86–98. doi:10.1016/j.arbr.2012.01.003
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee YK, Kim EK, et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir Med. 2010;104(4):542–549. doi:10.1016/j.rmed.2009.10.024
   PubMed Web of Science ®Google Scholar
• Avdeev S, Aisanov Z, Arkhipov V, et al. Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms. Int J Chron Obstruct Pulmon Dis. 2019;14:1267–1280. doi:10.2147/COPD.S207775
   PubMed Web of Science ®Google Scholar
• Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J. 2015;45(2):525–537. doi:10.1183/09031936.00128914
   PubMed Web of Science ®Google Scholar
• Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011;66(8):699–708. doi:10.1136/thx.2011.160028
   PubMed Web of Science ®Google Scholar
• Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001–1006. doi:10.1016/j.amjmed.2010.06.019
   PubMed Web of Science ®Google Scholar
• Agusti A, Fabbri LM, Singh D, et al. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J. 2018;52(6):1801219. doi:10.1183/13993003.01219-2018
   PubMed Web of Science ®Google Scholar
• Yawn BP, Li Y, Tian H, Zhang J, Arcona S, Kahler KH. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J Chron Obstruct Pulmon Dis. 2013;8:295–304. doi:10.2147/COPD.S42366
   PubMed Web of Science ®Google Scholar
• Kaplan AG. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice. Int J Chron Obstruct Pulmon Dis. 2015;10(1):2535–2548. doi:10.2147/COPD.S93321
   PubMedGoogle Scholar
• Janson C, Lisspers K, Ställberg B, et al. Osteoporosis and fracture risk associated with ICS use among Swedish COPD patients: the ARCTIC study. Eur Respir J. 2020:2000515. doi:10.1183/13993003.00515-2020.
   Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222–2256. doi:10.1056/NEJMoa1516385
   PubMed Web of Science ®Google Scholar
• Ulrik CS, Hansen EF, Jensen MS, et al. Management of COPD in general practice in denmark-participating in an educational program substantially improves adherence to guidelines on behalf of the KVASIMODO II Study Group. Int J Chron Obstruct Pulmon Dis. 2010;5:73. doi:10.2147/COPD.S9102
   PubMedGoogle Scholar
• Wouters EFM, Postma DS, Fokkensà B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial for the COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group. Thorax. 2005;60:480–487. doi:10.1136/thx.2004.034280
   PubMed Web of Science ®Google Scholar
• Rossi A, Van Der Molen T, Del Olmo R, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J. 2014;44(6):1548–1556. doi:10.1183/09031936.00126814
   PubMed Web of Science ®Google Scholar
• Rossi A, Guerriero M, Corrado A, et al. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res. 2014;15(1). doi:10.1186/1465-9921-15-77
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Worth H, Buhl R, et al. Real-life inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD. Int J Chron Obstruct Pulmon Dis. 2017;12:487–494. doi:10.2147/COPD.S125616
   PubMed Web of Science ®Google Scholar
• Van Der Valk P, Monninkhof E, Van Der Palen J, Zielhuis G, Van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the cope Study. Am J Respir Crit Care Med. 2002;166(10):1358–1363. doi:10.1164/rccm.200206-512OC
   PubMed Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–1294. doi:10.1056/NEJMoa1407154
   PubMed Web of Science ®Google Scholar
• Chalmers J, Bobak A, Scullion J, Murphy A. Withdrawal of ICS treatment in primary care: a practical guide. Pract Nurs. 2017;28(1):22–27. doi:10.12968/pnur.2017.28.1.22
   Google Scholar
• Chalmers JD. POINT: should an attempt be made to withdraw inhaled corticosteroids in all patients with stable GOLD 3 (30% ≤ FEV1 < 50% predicted) COPD? Yes. Chest. 2018;153(4):778–782. doi:10.1016/j.chest.2018.01.029
   PubMed Web of Science ®Google Scholar
• Chapman KR, Hurst JR, Frent S-M, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329–339. doi:10.1164/rccm.201803-0405OC
   PubMed Web of Science ®Google Scholar